{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-016574","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2025-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.342812+00:00","generated_at":"2026-05-18T18:23:47.010728+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MAIA Biotechnology enters $587,905 stock purchase agreement with Prevail Partners for Phase 3 THIO trial","bullets":["Total purchase amount up to $587,905; monthly payments equal to 33% of invoices for Phase 3 THIO trial services provided by Prevail affiliate InfoWorks.","Share price set at 120% of 30-day VWAP; minimum share price of $1.74; maximum shares issuable at minimum price: 337,876.","Shares are unregistered, issued under Section 4(a)(2); subject to 19.99% blocker and Exchange Cap.","Proceeds used to fund a multicenter Phase 3 study of THIO sequenced with cemiplimab in advanced NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-016574","json":"https://secwatch.observer/filing/0001641172-25-016574.json","markdown":"https://secwatch.observer/filing/0001641172-25-016574.md","text":"https://secwatch.observer/filing/0001641172-25-016574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000164117225016574/0001641172-25-016574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000164117225016574/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T18:23:47.010728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}